Herantis Pharma Plc announced that it has named eminent international pharmaceutical expert Dr. Anders Gersel Pedersen to its new scientific advisory board as Chairman. Dr. Pedersen brings impeccable experience, expertise and track record in the pharmaceutical industry and the development of new drugs for CNS diseases. Dr. Pedersen spent nineteen years at Lundbeck from 2000 to 2019, seven years of which he lead the R&D organization as Executive Vice President of Research & Development from 2013 - 2019. Anders is currently a member of the board of Hansa Biopharma, where he also is Chairman of the scientific committee. He has served since 2003 on the board of Genmab (previously as Chairman), a leading biotechnology company focused on development and specialisation of antibody products and he has served since 2009 on the board of Bavarian Nordic (currently as Deputy Chairman), a biotechnology company specialized in vaccines.